Cencora Inc.
COR
Market Cap$47.34B
Close$
Earnings Call Q1 2024
January 31, 2024 - AI Summary
Cencora reported strong first quarter results, with revenue up 15% year-over-year to over $72 billion and adjusted earnings per share up 21%.
The company raised its fiscal 2024 full year guidance, reflecting the strength of its business and opportunities in the pharmaceutical market.
Cencora's core pharmaceutical distribution business showed outsized operating income growth, driven by strong volumes, favorable pricing trends, and effective expense management.
Exclusive for Stockcircle Pro members
Sign up
$530.55
123% upside
Current Fair Value
123% upsideUndervalued by 123% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.34 Billion |
|---|---|
| Enterprise Value | $49.24 Billion |
| Dividend Yield | $1.9876 (0.84%) |
| Earnings per Share | $9.18 |
| Beta | 0.07 |
| Outstanding Shares | 199,481,993 |
| Avg 30 Day Volume | 973,609 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 25.35 |
|---|---|
| PEG | 99.9 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 59.49 |
| Enterprise Value to Revenue | 0.18 |
| Enterprise Value to EBIT | 17.57 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 5.24 |
Revenue Sources
No data
ESG Score
No data
About CoreSite Realty Corporation
CEO: Paul Szurek